In acute myeloid leukemia (AML) with TP53 mutations, the therapeutic agent DNA methyltransferase inhibitors (DNMTis) expressed endogenous retroviruses (ERVs), IFNs and activated NLRP3 inflammasome in a STING-dependent manner [201]. The gene discussed is STING1; the disease is acute myeloid leukemia.